Balloon Enteroscopy-Assisted ERCP and EUS-Guided Biliary Drainage for Malignant Biliary Obstruction in Patients With Surgically Altered Anatomy: A Systematic Review and Meta-Analysis.

Dig EndoscOct 1, 2026
Clinical ResearchGastroenterology

Masahiro Itonaga, Ke Wan, Tamura Takashi et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis assessed balloon enteroscopy-assisted ERCP (BEA-ERCP) versus EUS-guided biliary drainage (EUS-BD) for malignant biliary obstruction in patients with surgically altered anatomy. The analysis included 13 studies, revealing that EUS-BD had a higher pooled technical success rate of 97% compared to 75% for BEA-ERCP.

Key findings

  • Pooled technical success rates were 75% for BEA-ERCP and 97% for EUS-BD.
  • Pooled clinical success rates were 72% for BEA-ERCP and 92% for EUS-BD.
  • Adverse event rates were 11% for BEA-ERCP and 17% for EUS-BD.
  • Recurrent biliary obstruction rates were 26% for BEA-ERCP and 23% for EUS-BD.

Why it matters

Understanding the comparative effectiveness of BEA-ERCP and EUS-BD is crucial for optimizing treatment strategies for malignant biliary obstruction, particularly in patients with altered anatomy, where procedural success can significantly impact patient outcomes.

Source

PubMed · PMID 42830465

Published in Dig Endosc. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Gastroenterology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.